[charbonneau]

Press release [1]:

> CureVac estimates that the earliest potential approval of [first-generation vaccine] would come in the second quarter of 2022. By this time, the companies expect the candidates from the second-generation vaccine program to have progressed to late-stage clinical development.

What's the goal of having a COVID vaccine market ready in the third/fourth quarter of 2022? And how will they achieve it? Will it be authorized under an Emergency Use Authorization? Do they anticipate that the circumstances justifying EUA's will continue?

[1] https://www.curevac.com/en/2021/10/12/curevac-to-shift-focus...